Soligenix Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix Inc. (NASDAQ:SNGX) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 809,139 shares, a growth of 22.2% from the March 31st total of 662,209 shares. Based on an average trading volume of 157,625 shares, the short-interest ratio is currently 5.1 days. Approximately 8.1% of the company’s shares are short sold.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SNGX. XTX Topco Ltd acquired a new stake in shares of Soligenix in the fourth quarter valued at $37,000. StoneX Group Inc. acquired a new stake in shares of Soligenix in the fourth quarter valued at $50,000. Jane Street Group LLC acquired a new stake in shares of Soligenix in the fourth quarter valued at $51,000. Banco BTG Pactual S.A. acquired a new stake in shares of Soligenix in the third quarter valued at $54,000. Finally, Virtu Financial LLC acquired a new stake in shares of Soligenix in the third quarter valued at $59,000. 3.60% of the stock is currently owned by institutional investors and hedge funds.

Soligenix Stock Down 1.2%

NASDAQ:SNGX traded down $0.00 during trading hours on Friday, reaching $0.34. 841,848 shares of the stock were exchanged, compared to its average volume of 473,449. The business has a 50-day moving average of $1.15 and a two-hundred day moving average of $1.31. Soligenix has a twelve month low of $0.32 and a twelve month high of $6.23. The company has a market capitalization of $3.51 million, a price-to-earnings ratio of -0.10 and a beta of 1.93.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.00.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.